Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 20 | 2018 | 110 | 5.290 |
Why?
|
| Quality of Life | 11 | 2018 | 541 | 1.310 |
Why?
|
| Severity of Illness Index | 11 | 2018 | 814 | 0.840 |
Why?
|
| Health Status | 4 | 2017 | 195 | 0.840 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2017 | 476 | 0.710 |
Why?
|
| Fatigue | 2 | 2018 | 45 | 0.690 |
Why?
|
| Surveys and Questionnaires | 7 | 2017 | 1042 | 0.670 |
Why?
|
| Adult | 17 | 2018 | 7255 | 0.590 |
Why?
|
| Rheumatologists | 1 | 2017 | 12 | 0.550 |
Why?
|
| Lupus Nephritis | 1 | 2017 | 25 | 0.540 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 24 | 0.540 |
Why?
|
| Middle Aged | 16 | 2018 | 8294 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 99 | 0.500 |
Why?
|
| Biological Products | 1 | 2016 | 39 | 0.490 |
Why?
|
| Female | 19 | 2018 | 14048 | 0.470 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 32 | 0.440 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 598 | 0.400 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 20 | 0.400 |
Why?
|
| Pain | 4 | 2018 | 382 | 0.400 |
Why?
|
| Psychometrics | 5 | 2017 | 197 | 0.390 |
Why?
|
| Humans | 22 | 2018 | 24703 | 0.390 |
Why?
|
| Male | 15 | 2018 | 13669 | 0.390 |
Why?
|
| Emotions | 3 | 2017 | 72 | 0.380 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2004 | 247 | 0.360 |
Why?
|
| Body Image | 2 | 2017 | 20 | 0.250 |
Why?
|
| Canada | 2 | 2016 | 42 | 0.240 |
Why?
|
| Linear Models | 4 | 2018 | 234 | 0.240 |
Why?
|
| Self Report | 3 | 2017 | 199 | 0.230 |
Why?
|
| Cross-Cultural Comparison | 2 | 2016 | 28 | 0.230 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 6 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 193 | 0.230 |
Why?
|
| Chlamydia trachomatis | 1 | 2004 | 5 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2004 | 5 | 0.220 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 43 | 0.220 |
Why?
|
| Depressive Disorder | 2 | 2018 | 167 | 0.220 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2004 | 6 | 0.220 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 412 | 0.200 |
Why?
|
| Factor Analysis, Statistical | 3 | 2017 | 50 | 0.200 |
Why?
|
| Antibodies, Antinuclear | 2 | 2017 | 8 | 0.190 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1293 | 0.190 |
Why?
|
| Pain Measurement | 4 | 2017 | 467 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 807 | 0.180 |
Why?
|
| Young Adult | 3 | 2016 | 1847 | 0.170 |
Why?
|
| Adolescent | 2 | 2016 | 1992 | 0.160 |
Why?
|
| Stress, Psychological | 2 | 2018 | 217 | 0.150 |
Why?
|
| Depression | 2 | 2013 | 390 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 286 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 304 | 0.140 |
Why?
|
| Blood Sedimentation | 1 | 2017 | 53 | 0.140 |
Why?
|
| Philippines | 2 | 2017 | 4 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2017 | 62 | 0.130 |
Why?
|
| Aged | 4 | 2017 | 8382 | 0.130 |
Why?
|
| Illinois | 1 | 2017 | 221 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2016 | 3208 | 0.130 |
Why?
|
| Mental Health | 1 | 2017 | 102 | 0.130 |
Why?
|
| Time Factors | 2 | 2017 | 1327 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 69 | 0.130 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 104 | 0.120 |
Why?
|
| Chicago | 1 | 2018 | 858 | 0.120 |
Why?
|
| Software | 1 | 2015 | 55 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 250 | 0.120 |
Why?
|
| Sleep | 1 | 2017 | 284 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 12 | 0.110 |
Why?
|
| Critical Pathways | 1 | 2014 | 17 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 314 | 0.110 |
Why?
|
| Goals | 1 | 2014 | 39 | 0.110 |
Why?
|
| Language | 1 | 2014 | 53 | 0.110 |
Why?
|
| Physicians | 1 | 2015 | 103 | 0.110 |
Why?
|
| Rheumatology | 1 | 2014 | 67 | 0.110 |
Why?
|
| Interferon Regulatory Factors | 1 | 2013 | 2 | 0.110 |
Why?
|
| Interferon Type I | 1 | 2013 | 8 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 253 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 85 | 0.100 |
Why?
|
| United States | 1 | 2016 | 1873 | 0.090 |
Why?
|
| California | 3 | 2017 | 31 | 0.080 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 17 | 0.070 |
Why?
|
| Cognition | 1 | 2014 | 1237 | 0.070 |
Why?
|
| Arthralgia | 1 | 2008 | 132 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 19 | 0.060 |
Why?
|
| Sulfasalazine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Lactones | 1 | 2004 | 9 | 0.060 |
Why?
|
| Sulfones | 1 | 2004 | 20 | 0.060 |
Why?
|
| Doxycycline | 1 | 2004 | 15 | 0.060 |
Why?
|
| Methotrexate | 1 | 2004 | 35 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2004 | 6 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 155 | 0.050 |
Why?
|
| Synovial Fluid | 1 | 2004 | 91 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2011 | 1748 | 0.050 |
Why?
|
| Pregnancy | 1 | 2004 | 315 | 0.050 |
Why?
|
| Osteoarthritis, Knee | 1 | 2008 | 361 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 101 | 0.050 |
Why?
|
| Prevalence | 1 | 2004 | 411 | 0.050 |
Why?
|
| Hypertension | 1 | 2004 | 169 | 0.050 |
Why?
|
| Comorbidity | 1 | 2004 | 447 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 279 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2004 | 384 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 81 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 315 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 362 | 0.040 |
Why?
|
| Japan | 1 | 2016 | 6 | 0.030 |
Why?
|
| Social Class | 1 | 2017 | 59 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 24 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 84 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 163 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2016 | 107 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 728 | 0.030 |
Why?
|
| DNA | 1 | 2013 | 97 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2013 | 56 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2014 | 252 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 240 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 555 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2011 | 26 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 38 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 571 | 0.010 |
Why?
|
| Knee Joint | 1 | 2008 | 744 | 0.010 |
Why?
|